vs

Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and 1ST SOURCE CORP (SRCE). Click either name above to swap in a different company.

AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $113.1M, roughly 1.6× 1ST SOURCE CORP). 1ST SOURCE CORP runs the higher net margin — 35.3% vs 0.9%, a 34.4% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 8.7%). 1ST SOURCE CORP produced more free cash flow last quarter ($58.1M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 7.8%).

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

1st Source Corporation is a financial services company headquartered in South Bend, Indiana. It operates 1st Source Bank, a bank with 81 branches in Indiana and Michigan. The bank's Specialty Finance Group provides financing for aircraft, trucks, and construction equipment. 1st Source Insurance provides insurance products and services.

FOLD vs SRCE — Head-to-Head

Bigger by revenue
FOLD
FOLD
1.6× larger
FOLD
$185.2M
$113.1M
SRCE
Growing faster (revenue YoY)
FOLD
FOLD
+15.0% gap
FOLD
23.7%
8.7%
SRCE
Higher net margin
SRCE
SRCE
34.4% more per $
SRCE
35.3%
0.9%
FOLD
More free cash flow
SRCE
SRCE
$42.2M more FCF
SRCE
$58.1M
$16.0M
FOLD
Faster 2-yr revenue CAGR
FOLD
FOLD
Annualised
FOLD
29.5%
7.8%
SRCE

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FOLD
FOLD
SRCE
SRCE
Revenue
$185.2M
$113.1M
Net Profit
$1.7M
$40.0M
Gross Margin
85.7%
Operating Margin
8.6%
45.4%
Net Margin
0.9%
35.3%
Revenue YoY
23.7%
8.7%
Net Profit YoY
-88.5%
6.5%
EPS (diluted)
$0.00
$1.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FOLD
FOLD
SRCE
SRCE
Q1 26
$113.1M
Q4 25
$185.2M
$110.8M
Q3 25
$169.1M
$110.7M
Q2 25
$154.7M
$108.2M
Q1 25
$125.2M
$104.0M
Q4 24
$149.7M
$97.8M
Q3 24
$141.5M
$97.9M
Q2 24
$126.7M
$97.3M
Net Profit
FOLD
FOLD
SRCE
SRCE
Q1 26
$40.0M
Q4 25
$1.7M
$41.1M
Q3 25
$17.3M
$42.3M
Q2 25
$-24.4M
$37.3M
Q1 25
$-21.7M
$37.5M
Q4 24
$14.7M
$31.4M
Q3 24
$-6.7M
$34.9M
Q2 24
$-15.7M
$36.8M
Gross Margin
FOLD
FOLD
SRCE
SRCE
Q1 26
Q4 25
85.7%
Q3 25
88.5%
Q2 25
90.2%
Q1 25
90.7%
Q4 24
90.1%
Q3 24
90.6%
Q2 24
91.1%
Operating Margin
FOLD
FOLD
SRCE
SRCE
Q1 26
45.4%
Q4 25
8.6%
Q3 25
20.3%
49.7%
Q2 25
-6.1%
44.5%
Q1 25
-6.3%
45.8%
Q4 24
10.7%
Q3 24
15.3%
46.3%
Q2 24
11.8%
49.1%
Net Margin
FOLD
FOLD
SRCE
SRCE
Q1 26
35.3%
Q4 25
0.9%
37.1%
Q3 25
10.2%
38.2%
Q2 25
-15.8%
34.5%
Q1 25
-17.3%
36.1%
Q4 24
9.8%
32.1%
Q3 24
-4.8%
35.7%
Q2 24
-12.4%
37.8%
EPS (diluted)
FOLD
FOLD
SRCE
SRCE
Q1 26
$1.63
Q4 25
$0.00
$1.67
Q3 25
$0.06
$1.71
Q2 25
$-0.08
$1.51
Q1 25
$-0.07
$1.52
Q4 24
$0.05
$1.27
Q3 24
$-0.02
$1.41
Q2 24
$-0.05
$1.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FOLD
FOLD
SRCE
SRCE
Cash + ST InvestmentsLiquidity on hand
$293.5M
Total DebtLower is stronger
$392.7M
Stockholders' EquityBook value
$274.2M
$1.3B
Total Assets
$949.9M
$9.1B
Debt / EquityLower = less leverage
1.43×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FOLD
FOLD
SRCE
SRCE
Q1 26
Q4 25
$293.5M
Q3 25
$263.8M
Q2 25
$231.0M
Q1 25
$250.6M
Q4 24
$249.9M
Q3 24
$249.8M
Q2 24
$260.1M
Total Debt
FOLD
FOLD
SRCE
SRCE
Q1 26
Q4 25
$392.7M
Q3 25
$392.0M
Q2 25
$391.3M
Q1 25
$390.7M
Q4 24
$390.1M
Q3 24
$389.5M
Q2 24
$388.9M
Stockholders' Equity
FOLD
FOLD
SRCE
SRCE
Q1 26
$1.3B
Q4 25
$274.2M
$1.3B
Q3 25
$230.4M
$1.2B
Q2 25
$204.3M
$1.2B
Q1 25
$193.6M
$1.2B
Q4 24
$194.0M
$1.1B
Q3 24
$178.8M
$1.1B
Q2 24
$132.5M
$1.0B
Total Assets
FOLD
FOLD
SRCE
SRCE
Q1 26
$9.1B
Q4 25
$949.9M
$9.1B
Q3 25
$868.8M
$9.1B
Q2 25
$815.3M
$9.1B
Q1 25
$789.8M
$9.0B
Q4 24
$785.0M
$8.9B
Q3 24
$786.6M
$8.8B
Q2 24
$749.5M
$8.9B
Debt / Equity
FOLD
FOLD
SRCE
SRCE
Q1 26
Q4 25
1.43×
Q3 25
1.70×
Q2 25
1.92×
Q1 25
2.02×
Q4 24
2.01×
Q3 24
2.18×
Q2 24
2.93×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FOLD
FOLD
SRCE
SRCE
Operating Cash FlowLast quarter
$16.3M
$59.1M
Free Cash FlowOCF − Capex
$16.0M
$58.1M
FCF MarginFCF / Revenue
8.6%
51.4%
Capex IntensityCapex / Revenue
0.2%
0.9%
Cash ConversionOCF / Net Profit
9.62×
1.48×
TTM Free Cash FlowTrailing 4 quarters
$29.8M
$361.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FOLD
FOLD
SRCE
SRCE
Q1 26
$59.1M
Q4 25
$16.3M
$223.1M
Q3 25
$35.7M
$51.0M
Q2 25
$-26.5M
$44.9M
Q1 25
$7.8M
$71.8M
Q4 24
$-3.9M
$193.9M
Q3 24
$-23.0M
$68.4M
Q2 24
$22.7M
$50.0M
Free Cash Flow
FOLD
FOLD
SRCE
SRCE
Q1 26
$58.1M
Q4 25
$16.0M
$213.0M
Q3 25
$35.3M
$47.3M
Q2 25
$-28.9M
$43.0M
Q1 25
$7.5M
$69.3M
Q4 24
$-4.2M
$181.5M
Q3 24
$-23.3M
$66.7M
Q2 24
$21.6M
$46.4M
FCF Margin
FOLD
FOLD
SRCE
SRCE
Q1 26
51.4%
Q4 25
8.6%
192.2%
Q3 25
20.9%
42.7%
Q2 25
-18.7%
39.8%
Q1 25
6.0%
66.6%
Q4 24
-2.8%
185.5%
Q3 24
-16.5%
68.1%
Q2 24
17.0%
47.7%
Capex Intensity
FOLD
FOLD
SRCE
SRCE
Q1 26
0.9%
Q4 25
0.2%
9.1%
Q3 25
0.2%
3.4%
Q2 25
1.6%
1.7%
Q1 25
0.2%
2.4%
Q4 24
0.2%
12.6%
Q3 24
0.3%
1.7%
Q2 24
0.9%
3.7%
Cash Conversion
FOLD
FOLD
SRCE
SRCE
Q1 26
1.48×
Q4 25
9.62×
5.42×
Q3 25
2.06×
1.21×
Q2 25
1.20×
Q1 25
1.91×
Q4 24
-0.27×
6.17×
Q3 24
1.96×
Q2 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FOLD
FOLD

Other$105.8M57%
Galafold$64.8M35%
Pombiliti Opfolda$14.6M8%

SRCE
SRCE

Segment breakdown not available.

Related Comparisons